Inhalative administration of fibrinogen IIb/IIIa receptor antagonists for prompt acute therapy in the event of thrombus formatio
The effect of the intravenously administered fibrinogen IIb/IIIa receptor antagonist Tirofiban as a thrombocyte aggregation inhibitor is known and well investigated. Now, for the first time, the dispersal of Tirofiban in the form of an aerosol has been achieved, which allows application of the produced aerosol via inhalation. This has the advantage that the active ingredients are reabsorbed very quickly after deposition and rapidly reach a therapeutically active drug level in the blood, which leads to life-saving thrombocyte aggregation inhibition. With this the possibility for acute and immediate treatment of diseases which are caused by or in conjunction with thrombus formation is finally available.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Parallel Paths: Understanding Malaria Resistance in Chimpanzees and Humans
The closest relatives of humans adapt genetically to habitats and infections Survival of the Fittest: Genetic Adaptations Uncovered in Chimpanzees Görlitz, 10.01.2025. Chimpanzees have genetic adaptations that help them survive…
You are What You Eat—Stanford Study Links Fiber to Anti-Cancer Gene Modulation
The Fiber Gap: A Growing Concern in American Diets Fiber is well known to be an important part of a healthy diet, yet less than 10% of Americans eat the minimum recommended…
Trust Your Gut—RNA-Protein Discovery for Better Immunity
HIRI researchers uncover control mechanisms of polysaccharide utilization in Bacteroides thetaiotaomicron. Researchers at the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Julius-Maximilians-Universität (JMU) in Würzburg have identified a…